Revenue
2020
2021
2022
2023
2024
2025
Ab Science (AB)
Price€0.7320Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | €1.2M | €1.1M | €970,000 | €958,000 | €1.6M | €1.6M |
| Gross profit | €978,000 | €896,000 | €587,000 | €927,000 | €1.5M | €1.5M |
| Gross margin | 83.30% | 83.58% | 60.52% | 96.76% | 93.09% | 95.64% |
| Research & development | €2.1M | €3.9M | €10.5M | €13.3M | €11.2M | €12.8M |
| Operating expenses | €339,000 | €7.0M | €14.0M | €16.9M | €15.3M | €16.3M |
| Operating income | €639,000 | −€6.1M | −€13.4M | −€15.9M | −€13.8M | −€14.7M |
| Operating margin | 54.43% | −567.44% | −1,384.43% | −1,663.57% | −859.24% | −931.71% |
| EBITDA | €1.7M | −€4.9M | −€7.2M | −€11.6M | — | — |
| EBITDA margin | 142.50% | −458.68% | −740.52% | −1,210.33% | — | — |
| Net income | −€1.6M | −€7.8M | −€12.0M | −€13.6M | −€14.5M | −€15.0M |
| Net profit margin | −132.62% | −730.50% | −1,235.57% | −1,421.19% | −900.00% | −950.41% |
| Basic EPSper basic share | -€0.03 | -€0.15 | -€0.24 | -€0.29 | -€0.30 | -€0.34 |
| Diluted EPSper diluted share | -€0.03 | -€0.15 | -€0.24 | -€0.29 | -€0.30 | -€0.34 |